RLX Technology Inc. (RLX)

RLX Technology went public in January 2021 and in two years became China’s largest e-cigarette company by volume and revenue. The business model is straightforward: sell a battery-powered device that heats liquid nicotine (or, separately, a heated-tobacco stick), then earn high margins on the refillable pods or cartridges that customers buy repeatedly. In the United States and Europe, this category has consolidated around a handful of global players; in China, the market was younger, fragmented, and fast-growing when RLX entered. The company seized the opportunity, built brands, captured market share, and struck distribution deals with China’s tobacco conglomerate. Then the Chinese government essentially shut the market down.

The core opportunity: replacement for traditional smoking

Globally, e-cigarettes and heated-tobacco products are positioned as less harmful alternatives to smoking traditional cigarettes. Smokers are the target; the premise is that converting a cigarette user to an e-cigarette user is a harm-reduction win for health while still capturing the customer’s lifetime spending on nicotine. In China, that premise collided with public-health policy. The government views nicotine addiction itself as the harm, not just the smoke, and has moved aggressively to restrict e-cigarette sales and marketing to prevent new users (especially youth) from starting with vaping as their entry point to nicotine.

RLX’s business exploded in 2018–2021 because the regulatory environment was permissive and the market was enormous. China has the world’s largest smoking population — hundreds of millions of adult smokers — and a portion were curious about alternatives. RLX built a beloved brand through slick marketing, sponsorships, and influencer partnerships; its products were stylish, the pods came in appealing flavours, and the category was novel and cool. The company’s gross margins hit the high 60s because the hardware was a one-time sale and the pods were pure repeat revenue with minimal variable cost. RLX went public expecting continued growth.

The pivot: regulation crushes growth

In 2021, the same year RLX went public, the Chinese government restricted e-cigarette marketing and sales. By 2022–2023, regulations tightened further. Flavours were restricted; online sales were prohibited; advertising was banned; retailers faced pressure to stop selling. The government’s intent was clear: allow existing smokers who had already switched to continue using e-cigarettes (for harm reduction relative to cigarettes), but prevent the market from growing and prevent youth uptake.

RLX adjusted by pivoting toward a B-B2B model: selling devices and consumables to existing smokers through offline channels (convenience stores, tobacco shops) and directly to corporate customers. The company also began developing nicotine-replacement therapy (NRT) products that could be sold as medicinal goods rather than consumer products, opening a different regulatory path. But these moves are fundamentally different from the mass-market consumer growth the company envisioned.

How the business actually works now

RLX generates revenue from two sources. The hardware (devices and the first pods) generates a one-time transaction; margins are moderate because the company subsidises the hardware to drive trial. The consumables — refill pods — are bought repeatedly and carry 60+ percent gross margins because the incremental cost is trivial. The company also earns licensing revenue from white-label products sold by partners, and has begun exploring NRT and other nicotine-delivery formats.

The fundamental risk is regulatory. China controls all aspects of RLX’s business environment: it can restrict certain flavours, cap prices, prohibit online sales, limit retail locations, or ban the category entirely. The company has no recourse because it cannot challenge the government or lobby against restrictions. A change in political winds toward public health could cut the business by 50 percent overnight. The company cannot expand internationally easily because the US, Europe, and most developed countries have their own e-cigarette regulations that are already mature and hostile to Chinese companies.

The second risk is the sustainability of the installed base. RLX’s growth story depended on converting millions of cigarette smokers to e-cigarettes. That thesis is partly intact — existing users do buy refill pods — but the company cannot add new users efficiently. If existing customers gradually reduce consumption or age out of nicotine use, the refill-pod revenue base will shrink, and the company has no obvious way to grow it back.

The third risk is competition and commoditisation. China has dozens of e-cigarette brands; RLX is the leader but not unassailable. Without marketing, competitive advantages erode. Lower-cost competitors can copy the product and undercut price if margins are still high.

The fourth risk is the execution of the NRT pivot. If RLX can transition successfully to nicotine-replacement therapy sold through pharmacies and medical channels, it opens a more regulated but potentially more durable market. If that pivot stalls, the company is stuck in a contracting consumer market with uncertain margins.

To understand RLX, start with the company’s quarterly earnings calls and annual report, which detail revenue trends by channel, average revenue per user (ARPU) on the refill side, and gross margins. Watch the company’s commentary on regulatory developments and the evolution of the NRT business. The stock is extremely sensitive to Chinese regulatory announcements — any news that restricts the e-cigarette market sends RLX down immediately. Conversely, news that the company has secured medical-product status for an NRT product or has signed a major distribution deal can send it up. The company also faces currency risk because it earns revenue in yuan and lists on the US exchange in dollars. RLX is a binary story: either the company successfully navigates China’s regulatory tightening and builds a sustainable NRT business, or it faces long-term margin compression and stagnating volumes. The market reprices this thesis regularly on each regulatory signal from China.